drugset / Trial / NCT04818086
Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder
Phase 1/2
Completed
18 enrolled
Virginia Commonwealth University
National Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this research study is to test the safety, tolerability, drug interactions with buprenorphine-naloxone, and effectiveness lemborexant when used to treat Opioid Use Disorder.
Timeline
- Start
- 2021-05-03
- Primary completion
- 2023-04-20
- Completion
- 2023-04-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lemborexant | Small molecule | 10 mg | — |
| Comparator | Buprenorphine | Other / unclassified | 16 mg | Other |
| Comparator | Naloxone | Small molecule | 4 mg | Other |